Faeth Therapeutics Appoints Karen Vousden to Board (Class II Director)

What Happened
Faeth Therapeutics announced on Sept. 11, 2026 that its Board expanded from five to six directors and appointed Karen Vousden, Ph.D., as a Class II director effective immediately. Dr. Vousden will hold office until the company’s 2029 annual meeting and was also named to the Board’s Compensation Committee. She co‑founded Faeth in April 2019 and brings extensive cancer biology and leadership experience, including roles at The Francis Crick Institute and as a current director at Bristol Myers Squibb.

Key Details

• Board change: size increased from five to six directors; appointment effective Sept. 11, 2026.
• Term and committee: Class II director through the 2029 annual meeting; member of the Compensation Committee.
• Compensation: will receive the standard non‑employee director cash retainer and an initial equity award — an option to purchase 25,000 shares under the 2026 Equity Incentive Plan, exercise price = closing stock price on grant date. Options vest monthly over three years and accelerate on a Change in Control (subject to continuous service).
• Governance notes: no family relationships or related‑party transactions disclosed; Dr. Vousden will sign the company’s standard indemnification agreement.

Why It Matters
A new, experienced scientific leader and co‑founder joining the Board may strengthen Faeth’s governance and scientific oversight, particularly given Dr. Vousden’s prominence in cancer biology and public‑company board experience. Investors should note the dilution and potential future expense implications from the 25,000‑share option grant (standard director equity compensation) and that this appointment alters Board composition and committee membership.